FindTrial
Sign In

TNF Inhibitor

DRUG10 trials

Sponsors

Gilead Sciences, Eli Lilly and Company, Brigham and Women's Hospital, Gunay ER, Jeffrey Curtis

Conditions

Anti-Tumor Necrosis Factor DrugsEnthesitisJuvenile Idiopathic ArthritisPsoriatic ArthritisRheumatoid ArthritisSpondylarthritisSpondyloarthritisUlcerative Colitis

Phase 2

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
TerminatedNCT02862574
Gilead SciencesRheumatoid Arthritis
Start: 2016-12-15End: 2017-08-07Updated: 2018-06-27
Proof-of-concept study of BI 655130 add-on treatment in patients with mild-to-moderately active ulcerative colitis during TNF inhibitor therapy
Active, not recruitingNL-OMON47670
Boehringer Ingelheimbowel inflammation ulcerative colitis
Start: 2017-08-09Target: 6Updated: 2024-02-28

Phase 4

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
CompletedNCT03915964
Eli Lilly and CompanyRheumatoid Arthritis
Start: 2019-04-25End: 2025-05-28Updated: 2026-06-24
A Study of Baricitinib in Participants With Rheumatoid Arthritis
CompletedNCT04086745
Eli Lilly and CompanyRheumatoid Arthritis
Start: 2020-02-14End: 2025-05-19Updated: 2026-07-10
Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Spondyloarthritis
CompletedNCT04953871
Gunay ERAnti-Tumor Necrosis Factor Drugs, Enthesitis, Spondyloarthritis
Start: 2017-01-31End: 2018-01-31Updated: 2021-07-08
COVID-19 VaccinE Response in Rheumatology Patients
CompletedNCT05080218
Jeffrey CurtisPsoriatic Arthritis, Rheumatoid Arthritis, Spondylarthritis
Start: 2021-11-15End: 2024-05-28Updated: 2025-05-02
Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial
RecruitingNCT06653634
Oslo University HospitalJuvenile Idiopathic Arthritis
Start: 2024-10-24End: 2029-12-31Target: 150Updated: 2025-03-24

Unknown Phase

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints
CompletedNCT04772248
Brigham and Women's HospitalRheumatoid Arthritis
Start: 2021-02-22End: 2021-12-30Updated: 2022-03-02
Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints
CompletedNCT04798287
Brigham and Women's HospitalRheumatoid Arthritis
Start: 2021-03-10End: 2022-05-16Updated: 2022-06-22
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
NCT05702879
Insel Gruppe AG, University Hospital BernUlcerative Colitis
Start: 2023-09-06End: 2025-01-31Target: 240Updated: 2023-12-06

Related Papers

Moving towards optimized treatment for children and adolescents with juvenile idiopathic arthritis in sustained remission randomized to continue stable treatment, methotrexate withdrawal or tumor necrosis factor inhibitor withdrawal: study protocol for the Norwegian multi-center MOVE-JIA trial
Trials2026-02-17
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.
2022-01-13115 citations